Detalhe da pesquisa
1.
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Lancet Oncol;
25(4): 518-528, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38547895
2.
Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
Br J Cancer;
130(5): 769-776, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38184691
3.
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Oncologist;
25(2): e266-e275, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32043796
4.
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
BMC Cancer;
20(1): 352, 2020 Apr 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32334548
5.
[Canal anal carcinoma]. / Carcinomes du canal anal.
Rev Prat;
69(3): 311-317, 2019 Mar.
Artigo
em Francês
| MEDLINE
| ID: mdl-30983261
6.
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Lancet Oncol;
19(8): 1094-1106, 2018 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30042063
7.
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
BMC Cancer;
17(1): 574, 2017 Aug 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28841909
8.
Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event.
BMC Cancer;
16: 384, 2016 07 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27378078
9.
Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances.
Mol Diagn Ther;
28(2): 201-214, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38267771
10.
Prognostic Factors of Long-Term Outcomes after Primary Chemo-Radiotherapy in Non-Metastatic Anal Squamous Cell Carcinoma: An International Bicentric Cohort.
Biomedicines;
11(3)2023 Mar 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36979770
11.
Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE.
Radiother Oncol;
183: 109542, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36813175
12.
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Eur J Cancer;
162: 138-147, 2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34995900
13.
Posterior Reversible Encephalopathy Occurring During Treatment With Palbociclib.
Cureus;
13(7): e16604, 2021 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34447643
14.
What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort.
Dig Liver Dis;
53(6): 776-784, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33867291
15.
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.
Ther Adv Med Oncol;
12: 1758835920975356, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33329760
16.
Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial.
Clin Cancer Res;
25(7): 2109-2115, 2019 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30504426